Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.

BACKGROUND & AIMS Fatty liver disease is a common condition in the Western world. Fatty liver may progress to steatohepatitis and cirrhosis. It is not yet known whether fatty liver disease results in higher health care utilization and costs. METHODS We used data from the Study of Health in Pomerania (SHIP), Germany, to assess the relation of fatty liver disease to self-reported health care utilization and costs at baseline and 5 years. The SHIP is a general population cohort study of 4310 adults aged 20 to 79 years at baseline in Pomerania. Fatty liver disease was defined as the presence of a hyperechogenic pattern of the liver and elevated serum alanine aminotransferase (ALT) levels. RESULTS In multivariable analyses, average annual overall health care costs at baseline and follow-up measurement were significantly higher for individuals with sonographic fatty liver and increased serum ALT levels. For example, controlling for comorbid conditions, subjects with sonographic fatty liver disease and increased serum ALT levels had 26% higher overall health care costs at 5-year follow-up. Analyses also suggest that diabetes and cardiovascular disease might mediate the relation of fatty liver disease and health care utilization and costs. CONCLUSIONS Policies seeking to minimize costs associated with fatty liver disease might want to consider addressing behavioral risk factors of fatty liver disease.

[1]  Anirban Basu,et al.  Generalized Modeling Approaches to Risk Adjustment of Skewed Outcomes Data , 2003, Journal of health economics.

[2]  J. Wasem,et al.  Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation – ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). , 2005 .

[3]  U. John,et al.  Study of Health in Pomerania (SHIP): A health examination survey in an east German region: Objectives and design , 2005, Sozial- und Präventivmedizin.

[4]  A. Döring,et al.  Validation of a short qualitative food frequency list used in several German large scale surveys , 1998, Zeitschrift fur Ernahrungswissenschaft.

[5]  Jeanne M Clark,et al.  The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.

[6]  Federica Agostini,et al.  Nonalcoholic fatty liver disease and the metabolic syndrome , 2005, Current opinion in lipidology.

[7]  N. Sattar,et al.  Abc of Obesity , 2007 .

[8]  G. Targher.  Non‐alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[9]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[10]  U. John,et al.  Association Between Behavior-Dependent Cardiovascular Risk Factors and Asymptomatic Carotid Atherosclerosis in a General Population , 2002, Stroke.

[11]  C E Koop,et al.  Reducing health care costs by reducing the need and demand for medical services. The Health Project Consortium. , 1993, The New England journal of medicine.

[12]  A. Lonardo,et al.  'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. , 2006, Journal of hepatology.

[13]  U. John,et al.  Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. , 2005, World journal of gastroenterology.

[14]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[15]  Thomas Kohlmann,et al.  Menopausal status and hepatic steatosis in a general female population , 2007, Gut.

[16]  G. Marchesini,et al.  Diabetes and liver disease: an ominous association. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[17]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[18]  G. Bedogni,et al.  The epidemiology of fatty liver , 2004, European journal of gastroenterology & hepatology.

[19]  M. Daviglus.  Health care costs in old age are related to overweight and obesity earlier in life. , 2005, Health affairs.

[20]  James G Wright,et al.  The development of a comorbidity index with physical function as the outcome. , 2005, Journal of clinical epidemiology.

[21]  D. Alte,et al.  Alcohol consumption and health-services utilization in Germany. , 2006, Journal of studies on alcohol.

[22]  B. Popkin,et al.  Measuring the full economic costs of diet, physical activity and obesity‐related chronic diseases , 2006, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[23]  S. Wannamethee,et al.  Prospective Study of Serum γ-Glutamyltransferase and Risk of NIDDM , 1998, Diabetes Care.

[24]  M. Lean,et al.  Strategies for preventing obesity , 2006, BMJ : British Medical Journal.

[25]  B. Neuschwander‐Tetri.  Nonalcoholic steatohepatitis and the metabolic syndrome. , 2005, The American journal of the medical sciences.

[26]  G. Targher,et al.  Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. , 2007, Atherosclerosis.

[27]  Charles E. McCulloch,et al.  Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models , 2005 .

[28]  H. Hense,et al.  Trends in coronary risk factors in the WHO MONICA project. , 2001, International journal of epidemiology.

[29]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.